Evaluation of faecal lactoferrin as a morbidity biomarker in Schistosoma mansoni infection

Trop Med Int Health. 2022 Dec;27(12):1053-1058. doi: 10.1111/tmi.13826. Epub 2022 Nov 1.

Abstract

Objective: Lactoferrin is an 80 KDa iron-binding glycoprotein that plays a significant role in the innate immune system and is considered to be an important microbicide molecule. This study aimed to assess the concentration of lactoferrin in Schistosoma mansoni-infected cases before and after praziquantel treatment.

Methods: A cross-sectional study was carried out on 250 individuals aged from 5 to 30 years. Stool samples were examined for the presence of parasitic infections using Kato-Katz and formalin ethyl acetate techniques. All S. mansoni-positive cases were treated with praziquantel and stool samples were recollected 21 days later. Faecal lactoferrin level was determined before and after treatment.

Results: The prevalence of S. mansoni infection was 14.4%. Among 36 participants infected with S. mansoni, the cure rate was 91.7%. A statistically significant difference in the mean lactoferrin level before and after treatment was detected (1648.95 pg/ml ± 656.5 vs. 1162.8 pg/ml ± 356.8). This difference was statistically significant in the middle and older age groups, in males and in the absence of coinfection with other parasites.

Conclusion: Lactoferrin could be a promising biomarker associated with S. mansoni infection, however, it could not be used to assess the severity of infection.

Keywords: diagnosis; inflammatory marker; lactoferrin; praziquantel; schistosomiasis.

MeSH terms

  • Adolescent
  • Adult
  • Animals
  • Biomarkers
  • Child
  • Child, Preschool
  • Cross-Sectional Studies
  • Feces / parasitology
  • Humans
  • Lactoferrin
  • Male
  • Praziquantel
  • Prevalence
  • Schistosoma mansoni
  • Schistosomiasis mansoni* / epidemiology
  • Young Adult

Substances

  • Biomarkers
  • Lactoferrin
  • Praziquantel